By June, the ENERGY-1 trial for infants, targeting INZ-701's effect on ENPP1 Deficiency, started with results expected in late 2024. In July 2023, Inozyme outlined its ENERGY-3 trial, starting in ...

About INZ-701 INZ-701, an ENPP1 Fc fusion protein, is an enzyme replacement therapy (ERT) in development for the treatment of rare diseases linked to the PPi-Adenosine Pathway.

Patients were treated with INZ-701 for periods of three weeks to 22 months. The data presentation can be accessed here on Inozyme’s Investor Relations site. Key results include: Story Continues ...

INZ-701, an investigational enzyme replacement therapy (ERT), was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the EMA for the treatment of ENPP1 Deficiency.

Edward White’s rating is based on the promising interim data from the Phase 1 SEAPORT 1 trial and the potential market opportunity for Inozyme Pharma’s enzyme replacement therapy, INZ-701. The ...